WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406404
CAS#: 930089-25-1
Description: KI-328 is a novel KIT inhibitor. KI-328 shows selective potency against KIT kinase for the in vitro kinase assay, and inhibits the growth of wild-type (Wt)- and mutant-KIT-expressing cells, while it has little potency against D816V-KIT.
MedKoo Cat#: 406404
Name: KI-328
CAS#: 930089-25-1
Chemical Formula: C25H25N7O3
Exact Mass: 471.20189
Molecular Weight: 471.51
Elemental Analysis: C, 63.68; H, 5.34; N, 20.79; O, 10.18
KI-328 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: KI328; KI 328; KI-328.
IUPAC/Chemical Name: methyl (4-(2-((5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-(phenylamino)pyrimidin-2-yl)amino)ethyl)phenyl)carbamate
InChi Key: DRWABHOVZJWFLU-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H25N7O3/c1-34-25(33)29-19-11-7-16(8-12-19)13-14-26-24-27-15-20(23-32-31-22(35-23)17-9-10-17)21(30-24)28-18-5-3-2-4-6-18/h2-8,11-12,15,17H,9-10,13-14H2,1H3,(H,29,33)(H2,26,27,28,30)
SMILES Code: O=C(OC)NC1=CC=C(CCNC2=NC=C(C3=NN=C(C4CC4)O3)C(NC5=CC=CC=C5)=N2)C=C1
The following data is based on the product molecular weight 471.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Int J Hematol. 2010 Nov;92(4):624-33. doi: 10.1007/s12185-010-0692-8. Epub 2010 Oct 5. PubMed PMID: 20890793.